“Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC)” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s689. doi:10.25251/cpgrax68.